Samelisant is under clinical development by Suven Life Sciences and currently in Phase III for Narcolepsy. According to GlobalData, Phase III drugs for Narcolepsy have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Samelisant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Samelisant overview

Samelisant (SUVNG-3031) is under development for the treatment of cognitive impairment associated with Alzheimer's disease, schizophrenia, narcolepsy and narcolepsy associated with cataplexy. The drug candidate is administered orally in the form of tablet. The drug candidate acts by targeting histamine 3 (H3) receptor.

Suven Life Sciences overview

Suven Life Sciences (Suven), formerly Suven Pharmaceuticals is a company that designs, develops, manufactures, and supplies bulk actives, drug intermediates, and fine chemicals. The company offers active pharmaceutical ingredient products which include aripiprazole, calcium acetate, divalproex sodium, entacapone, fenoprofen calcium, gabapentin, glycopyrrolate, and others. It provides iron sucrose complex for injection, losartan potassium, malathion lotion, nitazoxanide and pamabrom. Suven’s intermediates include diethyl amino cyanoacetamide, dihydroxy nitrobenzaldehyde, triacetoxy deoxyribose and cyclobutanecarbonitrile. The company offers products in form of solutions, suspensions, emulsions, injectables, lyophilized formulations, ophthalmic and oral preparations, ointments, creams, and gels. The company operates in the US, Australia, India, and New Zealand. Suven is headquartered in Hyderabad, Telangana, India.

For a complete picture of Samelisant’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.